首页> 外国专利> Composition for preventing or treating allergic skin diseases which comprises GPCR 19 agonist as an active ingredient {Composition for preventing or treating allergic dermatitis comprising GPCR 19 agonist as an active ingredient}

Composition for preventing or treating allergic skin diseases which comprises GPCR 19 agonist as an active ingredient {Composition for preventing or treating allergic dermatitis comprising GPCR 19 agonist as an active ingredient}

机译:以GPCR 19激动剂为有效成分的预防或治疗过敏性皮肤病的组合物{以GPCR 19激动剂为有效成分的预防或治疗过敏性皮炎的组合物}

摘要

The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate(HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.
机译:本发明涉及含有G蛋白偶联受体19(GPCR19)激动剂,特别是牛磺脱氧胆酸钠(HY2191)及其衍生物作为预防或治疗过敏性皮肤病的有效成分的药物组合物,口服制剂和注射制剂。 。本发明还涉及用于预防和改善过敏性皮肤病的外用制剂和含有所述药物组合物的化妆品组合物。与目前使用的类固醇软膏或免疫抑制软膏相比,所述药物组合物在治疗和改善过敏性皮炎方面显示出优异的功效。所述药物组合物降低了血清IgE的水平,血清IgE是引起过敏性皮炎的主要因素,增加了TH1细胞因子,减轻了过敏性皮炎,并降低了TH2细胞因子,从而加剧了过敏性皮炎。所述药物组合物还减少了肥大细胞,嗜酸性粒细胞和嗜中性粒细胞在真皮中的浸润,并改善了临床症状,例如红斑,出血,水肿,剥落,糜烂,结垢和干燥。因此,所述药物组合物可以用于预防和治疗过敏性皮肤病。

著录项

  • 公开/公告号JP6542275B2

    专利类型

  • 公开/公告日2019-07-10

    原文格式PDF

  • 申请/专利权人 シャペロン インク.;

    申请/专利号JP20170020559

  • 发明设计人 ソン スンヨン;キム ヨンヒ;

    申请日2017-02-07

  • 分类号A61K31/575;A61K9/08;A61K9/14;A61K9/20;A61K9/48;A61K9/16;A61P17;A61P17/04;A61P37/08;A61P43;A61K8/63;A61Q1/06;A61Q1/12;A61Q5/02;A61Q5/12;A61Q19;A61Q19/10;

  • 国家 JP

  • 入库时间 2022-08-21 12:19:13

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号